Altimmune, Inc. — Director's Dealing 2022

Feb 4, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Altimmune, Inc. (ALT)
CIK: 0001326190
Period of Report: 2022-01-31

Reporting Person: Harris Matthew Scott (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-01-31	Common Stock, par value $0.0001	A	1800	$6.86	Acquired	7562	Direct
2022-02-01	Common Stock, par value $0.0001	M	6166	—	Acquired	13728	Direct
2022-02-01	Common Stock, par value $0.0001	F	2183	$7.98	Disposed	11545	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-02-01	Restricted Stock Units	$	M	6166	Disposed		Common Stock, par value $0.0001 (6166)	Direct
2022-02-02	Stock Options (option to buy)	$7.53	A	91600	Acquired	2032-02-02	Common Stock, par value $0.0001 (91600)	Direct
2022-02-02	Restricted Stock Units	$	A	31100	Acquired		Common Stock, par value $0.0001 (31100)	Direct

Footnotes

F1: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2021 through January 31, 2022.

F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 31, 2022.

F3: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.

F4: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs.

F5: The RSUs become vested and exercisable in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.

F6: Twenty-five percent of the shares underlying the option become vested and exercisable on February 2, 2023 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following February 2, 2023, subject to the reporting person's continued service through the applicable vesting date.

F7: The RSUs become vested and exercisable in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.